Skip to main content

Keyboard Shortcuts

Key Pair Function
Alt S Search Box
Alt T Top of Page
Alt H Home Page
Alt Index Button
Alt Next Button
Alt Prev Button
TLDEF Logo

TLDEF's Trans Health Project

Working for Transgender Equal Rights
Menu
  • Trans Health Insurance Tutorial
    • Choosing a Plan
    • Understanding Your Plan
    • Applying for Coverage
    • Understanding a Denial
    • Appealing a Denial
  • Resources
    • Health Insurance Medical Policies
    • Medical Organization Statements
    • State Health Insurance Laws and Guidance
    • Medicaid Regulations and Guidance
    • Gender Centers
    • Trans Health Care Providers
    • State Employee Health Plans
    • Financial Aid for Transgender Surgeries
  • Tools
    • Legal Analysis
    • Medical Necessity Literature Reviews
    • Reporting Medical Provider Discrimination
    • Training Materials for Advocates
    • Provider Medical Necessity Letter Checklists
  • About Us
    • About TLDEF's Trans Health Project
    • Privacy Policy
  • Contact Us
    • Contact TLDEF's Trans Health Project
    • Contact TLDEF
Previous Page
Prev
Home
Home
Up
Up
Next Page
Next
  •  Home
  • Resources
  • Health Insurance Medical Policies
  • Current: AmeriHealth - Treatment of Gender Dysphoria

Prev Index Gender Dysphoria/Reassignment [16 of 171] Next

AmeriHealth

Treatment of Gender Dysphoria


Policy: Treatment of Gender Dysphoria
Policy Number: 11.09.02h
Last Update: 2020-01-01
Issued in: Pennsylvania

Breast Reconstruction:

Breast augmentation is considered medically necessary and, therefore, covered, when all of the following criteria are met:

  • The individual has persistent, well-documented gender dysphoria in accordance with the criteria established in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, [DSM-5].
  • Breast augmentation is recommended by a qualified professional provider who has consistently monitored the individual up to the time of surgery.
    • One referral letter and/or chart documentation must be written from the mental health professional provider who consistently monitored the individual throughout their psychotherapy or any other evaluation to the professional provider who will be responsible for the individual's treatment.
  • The individual is at least 18 years of age.
  • The individual, unless medically contraindicated, has used feminizing hormones continuously and responsibly (which may include screenings and follow-ups with the professional provider) for a 12-month period.
  • The individual, if required by a mental health professional provider, has regularly participated in psychotherapy throughout the real-life experience at a frequency determined jointly by the individual and the mental health professional provider.
  • If the individual has significant medical or mental health concerns, they are reasonably well controlled.

Youth Services:

Puberty suppressing hormones (e.g., Supprelin LA® [histrelin acetate], Vantas® [histerlin acetate], Lupron Depot® [leuprolide acetate for depot suspension], Viadur® [leuprolide acetate implant], Eligard® [(leuprolide acetate for injectable suspension], Zoladex® [goserelin acetate implant], Trelstar® [triptorelin pamoate for injectable suspension]) are considered medically necessary and, therefore, covered, when all of the following criteria are met:

  • The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed), in accordance with criteria established in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, [DSM-5].
  • The individual has reached at least Tanner Stage 2 of development.
  • Gender dysphoria emerged or worsened with the onset of puberty.

Back to top

Updated on Nov 3, 2020

Donate Now Donate Now

Join Our Mailing List

Facebook Button Twitter Button Instagram Button
 Keyboard Shortcuts
 Privacy Policy
 TLDEF Website

Copyright © 2023 Transgender Legal Defense & Education Fund, Inc.  |  520 8th Avenue, Suite 2204, New York, NY 10018   Tel: 646.862.9396   Fax: 646.993.1684